Drugs that block Janus kinases are showing promise in diseases ranging from myelofibrosis to rheumatoid arthritis, but with the leading agent in line for approval questions remain about their optimal selectivity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Dolgin, E. Companies hope for kinase inhibitor JAKpot. Nat Rev Drug Discov 10, 717–718 (2011). https://doi.org/10.1038/nrd3571
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3571
This article is cited by
-
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Nature Medicine (2014)